| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
We analyzed the relationship between the chemosensitivity and gene expression profile in prostate cancer. We focused on the FGF-FGFR families and related molecules, and analyzed the clinical specimens of molecules of interest.
FGF19 was significantly higher in CRPC cases than in non-cancer cases and HSPC cases. Serum concentrations of FGF19 were correlated with disease progression in patients with CRPC. In addition, it was suggested that there was a correlation between response to chemo therapy and decrease of FGF19 concentration. And also, PRL1 showed high expression in relapsed cases in radical prostatectomy tissue specimens. In addition, PRL1 showed high expression in CRPC and high grade cases.
|
